FMR LLC & Abigail Johnson Maintain 14.999% Stake in ALX Oncology
Ticker: ALXO · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1810182
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, amendment, biotech, insider-hold
TL;DR
**FMR LLC and Abigail Johnson still own almost 15% of ALXO, a big vote of confidence!**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in ALX Oncology Holdings Inc. (ALXO) to 14.999% of the common stock, totaling 7,472,821 shares, as of February 9, 2024. This is an amendment to a previous filing, indicating a significant, though slightly adjusted, continued interest in the pharmaceutical company. For investors, this signals that a large institutional investor maintains a substantial position, which can be seen as a vote of confidence in ALXO's future prospects.
Why It Matters
A large institutional investor like FMR LLC holding nearly 15% of ALXO's stock suggests a strong belief in the company's long-term value, potentially reassuring current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a level of confidence.
Analyst Insight
Investors should view this continued significant institutional ownership as a positive signal, suggesting FMR LLC sees long-term value in ALX Oncology. This could warrant further research into ALXO's fundamentals and future prospects.
Key Numbers
- 7,472,821 — Shares Beneficially Owned (Represents the total number of ALX Oncology common stock shares held by FMR LLC and Abigail P. Johnson.)
- 14.999% — Percent of Class (Indicates the significant portion of ALX Oncology's common stock controlled by FMR LLC and Abigail P. Johnson.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, principal owner of FMR LLC
- ALX Oncology Holdings Inc. (company) — issuer of the common stock
- 7,472,821 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 14.999% (dollar_amount) — percentage of class beneficially owned
- February 9, 2024 (date) — date as of change for the filing
Forward-Looking Statements
- FMR LLC will maintain a significant ownership stake in ALX Oncology Holdings Inc. for the foreseeable future. (FMR LLC) — high confidence, target: 2025-02-09
FAQ
Who are the primary reporting persons in this SC 13G/A filing for ALX Oncology Holdings Inc.?
The primary reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing.
What is the total number of shares of ALX Oncology Holdings Inc. common stock beneficially owned by the reporting persons?
FMR LLC and Abigail P. Johnson beneficially own 7,472,821 shares of ALX Oncology Holdings Inc. common stock, as detailed in Item 4(a) and Item 7 on the cover pages.
What percentage of ALX Oncology Holdings Inc.'s common stock class do the reporting persons beneficially own?
The reporting persons beneficially own 14.999% of the common stock class, as indicated in Item 4(b) and Item 11 on the cover pages.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as marked with an 'x' in the appropriate box on the first page of the filing.
What is the CUSIP number for ALX Oncology Holdings Inc. common stock?
The CUSIP number for ALX Oncology Holdings Inc. common stock is 00166B105, as stated in Item 2(e) and on the cover pages.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding ALX ONCOLOGY HOLDINGS INC (ALXO).